Risk assessment based on gemline genomic mutation becomes important issue in cancer screening. We have conducted SEIREI-CARE (comprehensive assessment, risk and education) program, a genetic/familial assessment of breast, ovarian and pancreatic cancers, using next-generation sequencing multigene panel (MGP) testing. An artificial intelligence (AI) chatbot device is utilized to assess cancer risk according to the National Comprehensive Cancer Network Guidelines. From April to September 2021, 1,117 women out of 10,742 (10.6%) registered through AI chatbot, and 285 (24.9%) of them met the NCCN Guideline. The rate of clinical genetic counseling is limited to 9.1%, accordingly only 3 women tested by MGP during 6 months. An integrated and functional approach is required for nursing profession and medical staff to promote genetic medicine.